<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090982</url>
  </required_header>
  <id_info>
    <org_study_id>APHP211198</org_study_id>
    <secondary_id>2021-A01859-32</secondary_id>
    <nct_id>NCT05090982</nct_id>
  </id_info>
  <brief_title>Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis</brief_title>
  <acronym>SHADOW</acronym>
  <official_title>Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis/Objective : Patient-centered health care and shared decision making are key&#xD;
      components of increasing importance which are recommended by the French Haute Autorite de&#xD;
      Sante (HAS) and World Health Organization (WHO).&#xD;
&#xD;
      In the context of dermatology and atopic dermatitis, European guidelines has promoted an&#xD;
      active involvement from both patients and caregivers in therapeutic decisions at all stages&#xD;
      to achieve therapeutic success and the Task Force on Atopic Dermatitis (ETFAD) has promoted&#xD;
      the setting of treatment goals in a shared decision with the patient.&#xD;
&#xD;
      The main objective of this study is to develop and cross culturally validate a tool dedicated&#xD;
      to shared-decision in atopic dermatitis that can be used during routine dermatological&#xD;
      consultations.&#xD;
&#xD;
      The second objective is to better characterize patients seen in this context and to evaluate&#xD;
      patients' satisfaction when empowered by shared decision.&#xD;
&#xD;
      Method : We aim to develop a SDMt in AD following the recommendations of the International&#xD;
      Patient Decision Aid Standards (IPDAS) collaboration. Development will use a multistep&#xD;
      approach: 1) identification of priority domains for patients; 2) Selection of domains to be&#xD;
      included in the SDMt for AD; and 3) Creation and testing of the SDMt.&#xD;
&#xD;
      Participants will be consecutive adult (&gt;18 years old) patients attending consultation for a&#xD;
      AD in medical centres in France (Toulouse, Nantes and Créteil). All participants will provide&#xD;
      written consent to participate. The study will be submitted for approbation to the local&#xD;
      ethics committees of the University Hospital Centres of Paris and will be conducted according&#xD;
      to the Declaration of Helsinki.&#xD;
&#xD;
      Step 1: Identification of priority domains for patients&#xD;
&#xD;
      Step 2: Selection of domains to be included in the SDMt for AD&#xD;
&#xD;
      Step 3: Creation and testing of the SDMt&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Creation of a shared medical decision-making tool in the context of a consultation for atopic dermatitis in a specialized dermatology consultation.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Qualitative descriptions of the topics discussed by the patient during the therapeutic decision in a specialized dermatology consultation for atopic dermatitis; in other words, to characterize the topics discussed by the patient during the consultation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with the therapeutic decision-making process</measure>
    <time_frame>during the intervention</time_frame>
    <description>SURE satisfaction score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the perceived state of the patient about the intervention</measure>
    <time_frame>during the intervention</time_frame>
    <description>Validation tool score CollaboRATE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the psychological state of the patient</measure>
    <time_frame>during the intervention</time_frame>
    <description>Validation tool score GAD-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the perceived health state of the patient</measure>
    <time_frame>during the intervention</time_frame>
    <description>Score of PHQ-9 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the quality of life of the patient</measure>
    <time_frame>during the intervention</time_frame>
    <description>Score of DLQI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the stigmatization perceived by the patient</measure>
    <time_frame>during the intervention</time_frame>
    <description>6-items Stigmatization scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the severity perceived by the patient</measure>
    <time_frame>during the intervention</time_frame>
    <description>Atopic Dermatitis Perceived Severity Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of treatment compliance in patients who received the validated tool</measure>
    <time_frame>during the intervention</time_frame>
    <description>Compliance with treatment received</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Patients with Atopic dermatitis</arm_group_label>
    <description>150 patients with Atopic dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Audio recordings during the consultations</intervention_name>
    <description>50 patients with audio recordings of the consultation</description>
    <arm_group_label>Patients with Atopic dermatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Audio recordings during the consultations and test of the shared medical decision-making tool for modification</intervention_name>
    <description>50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification</description>
    <arm_group_label>Patients with Atopic dermatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Audio recordings during the consultations and test of the shared medical decision-making tool for validation</intervention_name>
    <description>50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.</description>
    <arm_group_label>Patients with Atopic dermatitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Atopic Dermatitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years, male or female.&#xD;
&#xD;
          -  Patient with atopic dermatitis&#xD;
&#xD;
          -  Written information given to the patient and no objection from the patient to&#xD;
             participate to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient with cognitive dysfunction that makes it impossible to communicate effectively&#xD;
             or to complete the questionnaire&#xD;
&#xD;
          -  Patient under AME&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-André Natella, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled Ezzedine, MD</last_name>
    <phone>(0)149812504</phone>
    <phone_ext>+33</phone_ext>
    <email>khaled.ezzedine@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>64010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Khaled Ezzedine, MD</last_name>
      <phone>(0)1 49 81 25 04</phone>
      <phone_ext>+33</phone_ext>
      <email>khaled.ezzedine@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Khaled Ezzedine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>shared medical decision-making tool</keyword>
  <keyword>e-Delphi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>APHP IS DATA'S OWNER, PLEASE CONTACT BOARD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

